Drug Trial Radar · NCT06983743
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 5, 2025
Primary completion
May 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Conditions
- Metastatic Solid Tumors
Interventions
ERAS-0015Drug
ERAS-0015 Administered orally
ERAS-0015 in combinationDrug
ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 21
- Maximum tolerated dose (MTD)Time frame: Study Day 1 up to Day 21
- Recommended dose for expansion (RDE)Time frame: Study Day 1 up to Day 21
- Adverse EventsTime frame: Study Day 1 up to Day 21
- Plasma concentration (Cmax)Time frame: Study Day 1 up to 65
- Time to achieve Cmax (Tmax)Time frame: Study Day 1 up to 65
- Area under the curveTime frame: Study Day 1 up to 65
- Half-lifeTime frame: Study Day 1 up to 65
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Providence Medical Group
Santa Rosa, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Florida Cancer Specalists
Sarasota, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Massachusetts General Hospital (MG)
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Texas at Tyler
Tyler, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
The Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Seoul St. Mary's Hospital Clinical Trial Center
Seoul, South Korea · Recruiting
Inje University Haeundae Paik Hospital Clinical Trial Center
Haeundae, Busan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.